SCHEMBL5289610

SCHEMBL5289610

c1ccc2c(c1)CC(N1CCNCC1)=N2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 3/20 0.48
HTR3E A5X5Y0 1/20 0.48
HTR3B O95264 1/20 0.48
HTR3A P46098 1/20 0.48
HTR3D Q70Z44 1/20 0.48
HTR3C Q8WXA8 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
ACHE P22303 5/20 0.46
BCHE P06276 1/20 0.46
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
KMT2A Q03164 1/20 0.45
DRD2 P14416 1/20 0.43
PLD1 Q13393 1/20 0.42
HRH4 Q9H3N8 2/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13657721 0.84 ACHE (0.62) SIGMAR1ACHEBCHEMEN1USP2
SCHEMBL14042694 0.82 HRH4 (0.46) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL12559393 0.81 HRH4 (0.62) ACHEBCHEMEN1USP2ALDH1A1
SCHEMBL11119265 0.78 HRH4 (0.45) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL11625870 0.78 HTR1A (0.44) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL141985 0.78 HRH4 (0.71) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL14340724 0.74 ACHE (0.45) SIGMAR1ACHEBCHEMEN1USP2
SCHEMBL11877889 0.72 HRH4 (0.49) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL11665287 0.71 CETP (0.39) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL10956962 0.71 HTR2C (0.39) ADRB1HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-8481547-B2 Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1 JANSSEN PHARMACEUTICA NV (BE) 2013-07-09 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
US-20110152287-A1 SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 US disclosed
US-7501421-B2 Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-03-10 US disclosed
US-20070281945-A1 Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-12-06 US disclosed
EP-1636239-B1 INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC ACTIVITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 EP disclosed
US-4382935-A Analgesic drug containing a derivative of benzylpiperazine Buzas, Andre (FR) 1983-05-10 US disclosed
EP-0034521-B1 ANALGESIC DRUG CONTAINING 1-(3'-BENZOFURYL)-4-BENZYLPIPERAZINE AND PROCESS FOR ITS PREPARATION Buzas, André (FR) 1983-03-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281945-A1 Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2C ADRB1 250/4885HTR3E 15/4885HTR3B 5/4885
US-20110152287-A1 SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 DPP4, DPP7, DPP3 ADRB1 354/4885HTR3E 574/4885HTR3B 1020/4885
US-20120289495-A1 COMPOUNDS AND METHODS XDH, CCNY, TOP2B ADRB1 1245/4885HTR3E 515/4885HTR3B 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.